Android app on Google Play

Aastrom Bio (ASTM) Grantd Key Australian Patent for Ixmyelocel-T

December 19, 2013 9:06 AM EST Send to a Friend
Get Alerts ASTM Hot Sheet
Trade ASTM Now!
Join SI Premium – FREE
Aastrom Biosciences, Inc. (Nasdaq: ASTM) announced that it has been granted a key composition-of-matter patent from the Australian Patent Office for ixmyelocel-T, Aastrom's cell therapy product candidate.

The issued patient, entitled "Mixed Cell Populations for Tissue Repair and Separation Technique for Cell Processing," provides protection for key characteristics of ixmyelocel-T through 2027. Aastrom now holds patent protection for ixmyelocel-T in Australia, the United States and the European Union.

"Patent approval in Australia expands our opportunity to commercialize ixmyelocel-T in multiple therapeutic markets and consider a range of partnership opportunities and other strategies to advance ixmyelocel-T through clinical development," said Nick Colangelo, president and chief executive officer at Aastrom Biosciences.

Aastrom is currently conducting the Phase 2b ixCELL-DCM clinical study of ixmyelocel-T in the United States and Canada for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy, a progressive disease of heart muscle and a leading cause of heart failure and heart transplantation.

You May Also Be Interested In

Related Categories

Corporate News, FDA, Litigation, Management Comments

Add Your Comment